Granulocyte-macrophage colony stimulating factor treatment of febrile neutropenia following remission induction chemotherapy for acute leukemia.

Abstract

Recombinant human granulocyte macrophage colony stimulating factor (GM-CSF) was given for 2-6 days in 10 patients with febrile neutropenias following remission induction chemotherapy for acute leukemia (6 acute lymphoblastic and 4 acute myeloid leukemias) in which, broad spectrum and targeted antibiotherapy was ineffective. In 7 patients, the addition of GM-CSF helped overcome the serious infectious complications, leading to an accelerated neutrophil recovery averaging 18.4 days, significantly faster than in a historic group of 9 similar patients in whom GM-CSF was not given Side-effects of GM-CSF treatment were minor and reversible. GM-CSF treatment did not have any significant effect on the achievement of complete remission status.

• Authors: A Cucuianu, L Petrov, A Ghiurt, A Vasilache
• Journal: Romanian journal of internal medicine = Revue roumaine de medecine interne (Rom J Intern Med) 1996 Jan-Jun Vol. 34 Issue 1-2 Pg. 97-103 ISSN: 1220-4749 [Print] Germany
• PMID: 8908636 (Publication Type: Journal Article)

Chemical References

• Recombinant Proteins
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Chemotherapy, Adjuvant
• Drug Evaluation
• Female
• Fever (blood, drug therapy, etiology)
• Granulocyte-Macrophage Colony-Stimulating Factor (adverse effects, therapeutic use)
• Humans
• Leukemia, Myeloid, Acute (blood, complications, drug therapy)
• Leukemia, Myelomonocytic, Acute (blood, complications, drug therapy)
• Male
• Neutropenia (blood, drug therapy, etiology)
• Neutrophils (drug effects)
• Precursor Cell Lymphoblastic Leukemia-Lymphoma (blood, complications, drug therapy)
• Recombinant Proteins
• Remission Induction